Pular para o conteúdo principal
Ranking Invest

ELYM - Eliem Therapeutics, Inc.

Segmento: HealthcareEliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Análise Ranking Invest

Valuation estimado
$ 4.44 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 193.38 Mi

Dívida Líquida

-$ 28.55 Mi

L4T

-$ 98.23 Mi

Indicadores Básicos

ROE

-50.80%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

C0.44

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

D-0.23

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.15

DIV/L4T

0.29

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.